Consensus Grifols, S.A.

Equities

GRF

ES0171996087

Pharmaceuticals

Real-time Estimate Tradegate Other stock markets 10:17:35 09/12/2025 GMT			5-day change	1st Jan Change
10.84 ^EUR	+0.14%		+4.12%	+18.71%

12-04	Grifols achieves self-sufficiency in plasma-derived medicines in Egypt	RE
12-03	European Equities Traded in the US as American Depositary Receipts Higher in Wednesday Trading	MT

Evolution of the Average Target: Grifols, S.A.

Evolution of the Target Price: Grifols, S.A.

Changes in Analyst Recommendations: Grifols, S.A.

0354a0f3f6199c0381262f4419.udKbpoTO9Ry6cNMAIIYSCz9wN9bkxdCLY_tqLOX_ewE._b3L69G-uVv-FZFuc-JhR34WfO6Tr5LEJ6kEAdagGmf_5fPVybvNctUl6w~c4be3df2074b1e2595a282fe701b3eb4

Analysts' recommendations: Grifols, S.A.

11-06	Grifols lifts 2025 targets but fibrinogen delay and forex drag weigh on outlook
11-05	Invest Securities raises target price for Grifols
11-05	Spanish stocks - Factors to watch on Nov 5	RE
10-09	Spain's High Court summons Gotham City, GIP managers for market-related offence regarding Grifols	RE
09-29	Grifols creates strategy committee to advise board	RE
09-17	Alantra Equities Upgrades Grifols to Buy, Raises PT	MT
08-26	AlphaValue/Baader Europe Upgrades Grifols to Buy, Lifts PT	MT
08-07	Spanish stocks - Factors to watch on Aug 7	RE
07-31	BofA Keeps Grifols at Buy as Strong Q2 Offsets Currency Headwinds	MT
07-30	GRIFOLS : Exhibiting confidence by reinstating dividends
05-28	Barclays Keeps Grifols at Overweight on Growing Positive Momentum	MT
05-27	GRIFOLS : Governance and operational improvements are worthy of notice
05-14	AlphaValue/Baader Europe Keeps Grifols at Buy After Q1 Beat	MT
05-13	GRIFOLS : A healthy Q1 impressed investors
03-04	GRIFOLS : Invest Securities raises its price target
02-27	GRIFOLS : Q4 24: Investors impressed with FCF generation and governance-related announcements
01-28	Barclays Sees Upside Share Potential for Grifols Despite Price Target Cut Amid Headline Risks	MT
11-08	GRIFOLS : Invest Securities remains Buy, adjusts its target
11-08	GRIFOLS : No negative surprise in Q3 was good enough for the market
16/10/24	GRIFOLS : All eyes on the upcoming takeover bid, despite some normalisation in our estimates
31/07/24	GRIFOLS : Operational improvements continued in the Q2; guidance maintained
08/07/24	GRIFOLS : A strategic move or a ploy to arrest further shareholder wealth erosion?
15/05/24	GRIFOLS : In line Q1 and on track deleveraging; worth a go
11/04/24	GRIFOLS : Factoring in a more moderate earnings recovery; long-term view intact
01/03/24	Invest Securities Keeps Grifols at Buy, Trims PT	MT

More recommendations

Sector Comparison:

	Add to a list 0 selected To use this feature you must be a member Log in Sign up	Consensus	Analysts' recommendations evolution (4 months)	Financial estimates divergence	Analysts' Target price divergence	Objective/dr gap
	GRIFOLS, S.A.					+40.48%
	REGENERON PHARMACEUTICALS, INC.					+11.07%
	CSL LIMITED					+30.45%
	UCB					+6.39%
	SAMSUNG BIOLOGICS CO.,LTD.					+37.9%
	BIOGEN INC.					-0.93%
	INNOVENT BIOLOGICS, INC.					+28.48%
	INCYTE CORPORATION					+2.95%
	ALTEOGEN INC.					+13.97%
	BRIDGEBIO PHARMA, INC.					+14.02%
	Average					+18.48%
	Weighted average by Cap.					+18.24%

See all sector consensus

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

10.82EUR

Average target price

15.20EUR

Spread / Average Target

+40.48%

High Price Target

22.20EUR

Spread / Highest target

+105.18%

Low Price Target

9.000EUR

Spread / Lowest Target

-16.82%

Analyst Consensus Detail

Consensus revision (last 18 months)

Analysts covering the company

alphavalue	Abhishek Raval
Alantra Equities
AlphaValue/Baader Europe
Invest Securities
JPMorgan Chase
Credit Suisse
Morgan Stanley
Citigroup
Deutsche Bank Securities
HSBC